AI PRICE FORECAST
DHR Stock Forecast & AI Price Prediction
Danaher · Healthcare · Diagnostics & Research
DHR live signal snapshot
DHR last traded at $235.31, down 0.34% on the session, trading 3.1% below its 52-week high of $242.80 and 46.2% above its 52-week low of $160.93. The model's verdict for DHR right now: BUY (86% confidence). Short-term momentum is constructive: the 5-, 10- and 20-day moving averages are stacked upward and price is holding above the 50-day average. The model's one-month path points toward roughly $244.00 (3.7% from here).
On the 14-day relative strength index, DHR reads 55.5, showing buyers in control without the stretch of an overbought reading. Its MACD line is below its signal line with a negative histogram (-0.17) — downward momentum is accelerating. Its 50-day average ($221.62) is holding 10.3% above the 200-day ($200.89), the pattern chartists call a golden cross.
The average 12-month target from 21 Wall Street analysts is $259.90 (range $220.00–$310.00) — 10.5% upside from where DHR trades now. The current recommendation trend leans bullish: 20 Buy/Strong Buy ratings vs 0 Sell/Strong Sell (and 4 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive DHR dashboard for numbers updated throughout today's session.
About Danaher
Danaher Corporation (DHR) is a diagnostics & research company in the healthcare sector, headquartered in Washington, DC, United States. Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It has a market value of about $165.5 billion and roughly 58,000 full-time employees. Its beta of 0.8 means it has historically moved roughly in line with the market.
DHR performance vs. the market
Since the start of 2026 the stock has risen 2.8%, behind the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). On a one-year view it is up 11.4%, roughly in line with the S&P 500. The last month (+5.6%) continues the three-month advance (+15.4%).
| Period | DHR | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +5.6% | +11.4% | −2.3% |
| 3 months | +15.4% | +12.2% | −2.3% |
| Year to date | +2.8% | +22.1% | +11.4% |
| 1 year | +11.4% | +28.3% | +11.5% |
Danaher financials at a glance
In the quarter ended Sep 30, 2026, Danaher reported revenue of $6.6 billion and net income of $1.2 billion (a 18.8% net margin). Revenue was up 8.3% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 39.0 on trailing earnings of $6.04 per share. Trailing free cash flow was $4.7 billion, and total debt equals 52% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $6.6B | $1.2B |
| Jun 30, 2026 | $6.3B | $870M |
| Mar 31, 2026 | $6.0B | $1.0B |
| Dec 31, 2025 | $6.8B | $1.2B |
DHR vs. its peers
Against 5 of its largest healthcare peers, DHR's +2.8% year-to-date return beats 0 of them. The strongest of the group this year is Eli Lilly and (LLY, +33.7%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Danaher (DHR) | $235.31 | +2.8% | 39.0 | BUY |
| Thermo Fisher Scientific (TMO) | $717.71 | +23.9% | 37.9 | BUY |
| IDEXX Laboratories (IDXX) | $702.59 | +3.9% | 47.3 | BUY |
| Agilent Technologies (A) | $176.95 | +30.0% | 34.9 | BUY |
| IQVIA Holdings (IQV) | $274.53 | +21.8% | 33.4 | BUY |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
DHR stock: common questions
What is the DHR stock price target?
21 Wall Street analysts put the average 12-month target at $259.90, in a range of $220.00–$310.00, versus a recent price of $235.31. Stock Pulse 247's model projects about $244.00 over the next month.
Is DHR a buy right now?
Our AI model currently rates DHR a BUY at 86% confidence. Among analysts, 20 rate it Buy or Strong Buy, 4 Hold and 0 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has DHR stock performed this year?
Since the start of 2026 the stock has risen 2.8%, behind the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). On a one-year view it is up 11.4%, roughly in line with the S&P 500. The last month (+5.6%) continues the three-month advance (+15.4%).
What is DHR's 52-week high and low?
DHR has traded between $160.93 and $242.80 over the past 52 weeks; at $235.31 it is 3.1% below its 52-week high of $242.80 and 46.2% above its 52-week low of $160.93.
What sector is DHR in, and who are its peers?
DHR is in the healthcare sector (diagnostics & research). Its largest peers on Stock Pulse 247 include Thermo Fisher Scientific (TMO), IDEXX Laboratories (IDXX), Agilent Technologies (A), IQVIA Holdings (IQV).
How accurate is the DHR forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines DHR's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.